The first patient had a mean weight loss of 3.7 pounds and a mean BMI reduction of 0.6 after 10 weeks.
Loughborough, England, 24th January 2023–(BUSINESS WIRE)–Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”) develops and commercializes non-invasive wearable sensors and A medical technology company focused on lifestyle and weight loss support. The program presents the first results of a patient study of Metabolic Health His Program Miboko with the UK’s National Health Service (NHS).
An initial pilot program recruited 30 people classified as obese according to BMI. An initial cohort of 10 patients has been enrolled in the program for over 12 weeks. The results of this cohort show that these individuals achieved an average weight loss of 3.7 pounds and an improvement of 0.6 in her average BMI after her 10 weeks, with 100% of her participants achieving some weight improvement. is showing. This average weight loss level exceeds some of the results published in studies of other weight loss programs. Average weight loss is expected to increase as the Miboko program is optimized. The program is designed to last at least one year, with new patients enrolled each month.
Feedback from participants indicates that the use of body-worn sensors led to greater elements of engagement and gamification. This is expected to lead to sustained use and drive gradual changes in diet and lifestyle through a combination of personalized data and targeted educational modules. Participants expressed a willingness to continue with the program and reported that they did not view Miboko as a traditional diet plan. We hope this will avoid the diet fatigue and drop-off rates that are prevalent in many of today’s weight loss programs.
“These results validate a previously developed approach that integrates the use of non-invasive glucose sensors with personalized, app-driven coaching and analytics and are very encouraging,” said Faz Chowdhury, CEO. commented Dr. Nemaura Medical. “We look forward to continuing our research with the National Health Service and expect to see increasingly robust results as we continue to track these users and start new users each month.”
The Miboko program is the first to integrate a daily wear non-invasive glucose sensor with a lifestyle app. This includes food and drink records, educational content, and analytics platforms. The wellness program provides each user with a Metabolic Score based on sensor-determined diet, exercise, and glucose response to food intake. Users are provided personalized recommendations to help them lose weight, avoid potentially chronic health problems, and enjoy a better quality of life.
As research progresses, lessons learned are used to improve the program and introduce new features. The integration of Nemaura’s daily wear, non-invasive glucose sensor is a unique feature not found in any other plan, and the company now offers the option to offer the core part of the program and the glucose sensor as an add-on to existing diets. We are considering. We have a global metabolic health program.
We expect the UK National Health Service to publish detailed findings after further analysis.
About Miboko
Miboko integrates Nemaura’s non-invasive sensors with diet and wellness programs to provide indicators of a person’s metabolic health and wellness. Our partnership with the NHS in the UK is through medical centers affiliated with the NHS’s National Institute for Health and Care Research (NIHR) to collect information that can help make a difference and save lives. The research clinics are Research Ready accredited by the Royal College of General Practitioners and regularly conduct independent research.
Miboko is initially available without a prescription and is recommended for use by anyone wanting to lose weight and improve their general health and well-being. This program is relevant not only for obese people, but also for those with pre-diabetes. Importantly, Miboko is also used by people looking to start a diet program. Many of them have tried alternative diet plans. We have plans to collect long-term outcome data that may support reimbursement.
About Nemaura Medical
Nemaura Medical Inc. is a medical technology company that develops and commercializes non-invasive wearable diagnostic devices. The company is also currently commercializing sugarBEAT® and proBEAT™. A CE Mark approved Class IIb medical device, sugarBEAT® is a non-invasive, flexible continuous glucose monitor (CGM) that provides actionable insights from real-time glucose readings and daily glucose trend data. increase. It reverses and prevents the development of diabetes. Nemaura has submitted a PMA (Premarket Approval Application) for sugarBEAT® to the US FDA. proBEAT™ is non-invasive glucose data processed using artificial intelligence under a digital healthcare subscription service piloted in the US as a general wellness product as part of the BEAT® Diabetes Program is a combination of
We are at the intersection of the global type 2 diabetes market expected to reach approximately $59 billion by 2025, the pre-diabetes market of over $50 billion, and the wearable healthtech sector for weight loss and wellness applications. increase. Reach $60 billion by 2023.
Cautionary Note Regarding Forward-Looking Statements:
Statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and may cause actual future results to differ materially from those expressed or implied by such statements. Subject to possible risks and uncertainties. These risks and uncertainties include the launch of proBEAT™ in the United States, risks associated with the regulatory situation and failure of future development and preliminary marketing efforts, and Nemaura’s ability to secure additional commercial partnership agreements. , including but not limited to the associated risks and uncertainties. the ability of Nemaura and its partners to develop, market and sell his proBEAT™, the availability of substantial additional equity or debt capital to support its research;time, Development and product commercialization activities, including plans and strategies related to both proBEAT™ digital health and sugarBEAT®, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies. There is no assurance that the company will be able to reach any part or part of the global market for his CGM with its products/services. The U.S. Food and Drug Administration (“FDA”) reserves the right to re-evaluate its determination that proBEAT™ qualifies as a general wellness product. Misuse affecting patient safety, and any other reason that FDA, in its discretion, deems appropriate to determine that a product does not meet the definition of a general wellness product. There is no guarantee that KSA will approve registration of sugarBEAT® These and other risks and uncertainties are identified and described in more detail in Nemaura’s filings with the U.S. Securities and Exchange Commission. Quarterly Report on Form 10-Q and Current Report on Form 8-K. Nemaura undertakes no obligation to publicly update or revise any forward-looking statements.
For more information, please visit www.NemauraMedical.com.
View source version at businesswire.com: https://www.businesswire.com/news/home/20230124005604/en/
contact address
Core IR
Jules Abraham +1 917-885-7378
